We have located links that may give you full text access.
Case Reports
Journal Article
A case of refractory polyarteritis nodosa successfully treated with rituximab.
Modern Rheumatology 2017 July
A 59-year-old man who presented with continuous fever, livedo reticularis, and left leg ischemia with multiple tibial artery stenosis and renal artery aneurysm, as demonstrated by arteriography, was diagnosed with polyarteritis nodosa (PAN) 6 years ago. Although he frequently relapsed in spite of intensive immunosuppressive therapies, the disease activity of PAN was controlled with repeated rituximab (RTX) therapies and steroid doses were tapered safely. Peripheral CD19+ B-cells disappeared soon after the 1st administration of RTX. Although CD19+ B-cells remained absent, 3.1% of CD3+ CD20+ T-cells were observed in the peripheral blood prior to the 2nd administration of RTX. Recent studies have suggested the pathogenic role of CD3+ CD20+ T-cells in autoimmune diseases in the context of RTX therapy; therefore, their roles in the pathogenesis of PAN also need to be considered.
Full text links
Related Resources
Trending Papers
Ten tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation.Clinical Kidney Journal 2024 October
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes.Journal of Clinical Medicine 2024 October 18
Reinforced tension-line suture after laparotomy: early results of the Rein4CeTo1 randomized clinical trial.British Journal of Surgery 2024 September 3
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app